Navigation Links
InVitria's Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin

SACRAMENTO, Calif., Oct. 23 /PRNewswire/ -- InVitria has released data that shows that Lacromin, a recombinant growth factor for cell culture media outperforms transferrin and provides a cost-effective solution to rising transferrin costs. Because Lacromin is produced in a completely animal-free system, it provides improved productivity and safety over animal-derived alternatives including bovine and human transferrin. In addition data has shown that Lacromin significantly increased the productivity of antibody production when compared with these other sources of transferrin.

"We are excited about Lacromin and its success as safer, more productive replacement for transferrin," said Victor Hicks, Vice President and Commercial Director, InVitria. "Lacromin(TM) provides a cost-effective solution to the challenge of rising transferrin costs and increasing concern over the use of animal-derived ingredients in cell culture. Given the FDA's preference for non-animal derived cell culture media ingredients, animal-free recombinant proteins like Lacromin(TM) are a real breakthrough for this market."

InVitria markets Lacromin(TM) to customers that seek a serum-free and animal component free cell culture media source for their biopharmaceutical production.

About Lacromin(TM)

Lacromin(TM) is recombinant human lactoferrin derived from plants. Lacromin(TM) holds many advantages over current cell culture media ingredients:

-- Strong growth factor

Lacromin(TM) has been shown to promote cell growth in many cell lines,

including Chinese Hamster Ovary (CHO) cells and Mouse Hybridoma cells.

-- Outperforms Transferrin

Lacromin(TM) promotes higher cell density and reduces cell doubling

time when compared with Transferrin.

-- Replaces Animal Derived Transferrin

Since Lacromin(TM) is derived from plants, it is free of any viral or

prion contaminant risks.

-- Improves IgG Productivity

In Hybridoma cells, Lacromin(TM) increased IgG productivity by 50%

versus Transferrin and by 6% versus Fetal Bovine Serum (FBS).

About InVitria

InVitria is a global supplier of animal-free products for use in bioprocessing, excipients, research and diagnostics.

InVitria's mission is to develop and supply our customers with products that deliver faster time to market, enhanced productivity, and improved safety.

For more information about InVitria, see our website at

Or Contact:


Statements in this announcement other than historical data and information constitute forward looking statements that involve risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements. Potential risks and uncertainties may include, but are not limited to, recent changes in senior management, fluctuations in operating results, market conditions and changes in technology and increased competition.

Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. A Positive Selection Assay for Mutation Analysis in Big Blue Animals
2. Transgenic Animals
3. Bifidobacterium animalis
4. Bifidobacterium animalis
5. The QIAGEN Guide to Animal Cell Culture
6. The QIAGEN Guide to Animal Cell Culture
7. The QIAGEN Guide to Animal Cell Culture
8. The QIAGEN Guide to Animal Cell Culture
9. The QIAGEN Guide to Animal Cell Culture
10. The QIAGEN Guide to Animal Cell Culture
11. An Animal-Free DNase I
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon ... over 2,000 technical presentations offered in symposia, oral sessions, workshops, awards, and posters. ... a wide range of applications such as, but not limited to, biotechnology, biomedical, ...
(Date:11/25/2015)... -- PharmAthene, Inc. (NYSE MKT: PIP) announced  today that its ... (Rights Plan) in an effort to preserve the value ... 382 of the Internal Revenue Code (Code). ... its NOLs could be substantially limited if the Company ... of the Code. In general, an ownership change occurs ...
(Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) holds ... organisation (CRO) market. The trend of outsourcing to ... margins but higher volume share for the region ... scale, however, margins in the CRO industry will ... Market ( ), finds that the ...
Breaking Biology Technology:
(Date:11/10/2015)... NEW YORK , Nov. 10, 2015 /PRNewswire/ ... refers to behavioral biometrics that helps to identify ... prevent fraud. Signature is considered as the secure ... for the identification of a particular individual because ... offers more accurate results especially when dynamic signature ...
(Date:11/9/2015)... Calif. , Nov. 9, 2015  Synaptics Inc. ... interface solutions, today announced broader entry into the automotive ... solutions that match the pace of consumer electronics human ... biometric sensors are ideal for the automotive industry and ... Europe , ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has been ... provide preclinical development services to the National Cancer Institute ... will provide scientific expertise, modern testing and support facilities, ... preclinical pharmacology and toxicology studies to evaluate potential cancer ... The PREVENT Cancer Drug Development Program is an ...
Breaking Biology News(10 mins):